Intermediate flortaucipir uptake is associated with Aβ-PET and CSF tau in asymptomatic adults.

Neurology

From the Departments of Psychiatry (M.M., A.P.B., P.-F.M., J.G., H.O., P.R.-N., J.B., J.P., S.V.) and Neurology & Neurosurgery (P.R.-N., S.V.), McGill University; Douglas Mental Health University Institute (M.M., A.P.B., J.G., P.-F.M., C.B., H.O., A.L., P.R.-N., J.B., J.P., S.V.); and McConnell Brain Imaging Center, Montreal Neurological Institute (S.V., P.R.-N.), Montreal, Quebec, Canada.

Published: March 2020

AI Article Synopsis

  • The study aimed to explore how flortaucipir (FTP) levels relate to age and Alzheimer's disease indicators in asymptomatic adults at higher risk for the condition.
  • Results indicated that older age correlated with higher FTP retention in certain brain areas and that individuals with positive β-amyloid (Aβ) markers exhibited elevated FTP levels, which tied into cognitive performance and cerebrospinal fluid (CSF) tau levels.
  • The research suggests that low FTP-PET standardized uptake value ratios are linked to early Alzheimer's markers, emphasizing the need for tailored tau threshold adjustments based on different diagnostic purposes.

Article Abstract

Objective: To investigate relationships between flortaucipir (FTP) uptake, age, and established Alzheimer disease (AD) markers in asymptomatic adults at increased risk of AD.

Methods: One-hundred nineteen individuals with a family history of AD (Presymptomatic Evaluation of Experimental or Novel Treatments of Alzheimer's Disease [PREVENT-AD] cohort, mean age 67 ± 5 years) underwent tau-PET ([F]FTP), β-amyloid (Aβ)-PET ([F]NAV4694 [NAV]), and cognitive assessment. Seventy-four participants also had CSF phosphorylated tau and total tau data available. We investigated the association between age and FTP in this relatively young cohort of older adults. We also investigated regional FTP standardized uptake value ratio (SUVR) differences between Aβ-positive and Aβ-negative individuals and regional correlations between FTP and NAV retention. In cortical regions showing consistent associations across analyses, we assessed whether FTP was in addition related to CSF tau and cognitive performance. Lastly, we identified the lowest FTP value at which associations with Aβ-PET, CSF, and cognition were detectable.

Results: Increased age was associated only with amygdala and transverse temporal lobe FTP retention. Aβ-positive individuals had higher FTP SUVR values in several brain regions, further showing correlation with NAV load through the cortex. Increased FTP SUVRs in medial temporal regions were associated with increased CSF tau values and worse cognition. The SUVRs at which associations between entorhinal FTP SUVR and other AD markers were first detected differed by modality, with a detection point of 1.12 for CSF values, 1.2 for Aβ-PET, and 1.4 for cognition.

Conclusions: Relatively low FTP-PET SUVRs are associated with pathologic markers of AD in the preclinical phase of the disease. Adjustment in the tau threshold should be considered, depending on the purpose of the tau classification.

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000008905DOI Listing

Publication Analysis

Top Keywords

csf tau
12
ftp
10
aβ-pet csf
8
asymptomatic adults
8
regions showing
8
ftp suvr
8
tau
7
csf
6
intermediate flortaucipir
4
flortaucipir uptake
4

Similar Publications

Case-only designs in longitudinal cohorts are a valuable resource for identifying disease-relevant genes, pathways, and novel targets influencing disease progression. This is particularly relevant in Alzheimer's disease (AD), where longitudinal cohorts measure disease "progression," defined by rate of cognitive decline. Few of the identified drug targets for AD have been clinically tractable, and phenotypic heterogeneity is an obstacle to both clinical research and basic science.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Mayo Clinic, Jacksonville, FL, USA.

Background: The immune system is substantially involved in the development and progression of age-related cognitive decline and Alzheimer's disease (AD).

Method: As genetic and environmental factors interactively impact these conditions, we investigated how risk factors such as APOE genotype, age, and sex influence immune activation markers and AD biomarkers in cerebrospinal fluid (CSF) in elderly individuals enrolled in the Mayo Clinic Study of Aging cohort. Among cognitively unimpaired individuals aged over 65 at the baseline visit (N=298), we measured 365 CSF immune activation markers using the proximity extension assay.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Turner Institute for Brain and Mental Health & School of Psychological Sciences, Monash University, Clayton, VIC, Australia.

Background: Plasma and cerebrospinal (CSF) biomarkers are promising candidates for detecting neuropathology. While CSF biomarkers directly reflect pathophysiological processes within the central nervous system, their requirement for a lumbar puncture is a barrier to their widespread scalability in practice. Therefore, we examined cross-sectional associations of plasma biomarkers of amyloid (Aβ42/Aβ40 and pTau-181), neurodegeneration (Neurofilament Light, NfL), and neuroinflammation (Glial Fibrillary Acidic Protein, GFAP) with brain volume, cognition, and their corresponding CSF levels.

View Article and Find Full Text PDF

Background: This research introduces a novel method for quantifying aggregated tau in body fluids, specifically cerebrospinal fluid (CSF), aiming to enhance the diagnosis and monitoring of neurodegenerative diseases, with a focus on Alzheimer's disease (AD).

Method: By combining tau protein amplification with a highly sensitive single-molecule array (Simoa) immunoassay using an anti-tau antibody CT19.1 in a homogenous manner, the approach enables precise measurements of tau aggregates in CSF.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Background: The brain's ability to perform a cognitive task is a dynamic process and requires small blood vessels to dilate or constrict in real time to adjust blood flow in a region-specific manner. Cerebrovascular Reactivity (CVR) measures the ability of vessels to react to vasoactive challenges. In this work, we investigated the role of CVR as a possible biomarker in small vessel disease related vascular contributions to cognitive impairment and dementia (VCID), as part of the NINDS-funded MarkVCID study.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!